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ABSTRACT

Structural and Mechanistic Investigations of Phosphothreonine Lyase Class of Enzymes

by

Alok Gopalkrishna Shenoy, Master of Science
Utah State University, 2012

Major Professor: Prof. Alvan C. Hengge
Department: Chemistry and Biochemistry

The phosphothreonine lyase class of enzymes represents a recently discovered set of
enzymes that catalyze a dephosphorylation reaction. The catalysis is carried out using a unique
elimination mechanism without any involvement of cofactors. Crystallographic studies of SpvC,
a phosphothreonine lyase, and its mutant show that the mutation of the general catalytic acid
does not result in any significant perturbations to the tertiary and the secondary structure of the
protein. Using results from the structural studies and a deuterium isotope exchange experiment,
we conclude that the reaction catalyzed by SpvC may not involve formation of a carbanion at
the active site.

(56 Pages)
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PUBLIC ABSTRACT

Structural and mechanistic investigations of phosphothreonine lyase class of enzymes

Phosphorylation and dephosphorylation are a highly pervasive mechanism in biology
that is used by the cell to modulate enzymes and proteins. The presence of a phosphate group
can activate or deactivate an enzyme. The phosphate group is linked to a protein by a
phosphoester bond that is known to be highly stable in cytoplasmic pH range. Thus the breaking
and formation of these bonds need to be effected by enzymes.
Recent discovery of the activity carried out by certain virulence related proteins (OspF
released by Shigella and SpvC released by Salmonella) have resulted in a necessity to create a
new class of dephosphorylating enzymes – phosphothreonine lyases.
This class of proteins forms an important drug target against salmonella and shigella.
The objective of our work has been to decipher the mechanism by which these effector proteins
catalyze the dephosphorylation. Elimination reactions can be carried out by several
mechanisms, namely E1, E2, and E1cB. Identification of the mechanism will aid in drug design.
This report presents the results of analytical and crystallographic techniques used to study the
mechanism of the elimination catalyzed by SpvC.

Alok G. Shenoy

v

I dedicate the work presented herein to my Guru, my parents, in-laws, sunny and my wife
Padmashri Suresh.

vi
ACKNOWLEDGMENTS

I would like to thank Prof. Alvan C. Hengge for allowing me to pursue research in his
esteemed lab. His patience and mentorship have been instrumental in achieving the body of
work presented here. I would also like to thank my committee members, Prof. Sean J. Johnson,
who lent me his valuable time and resources during my training in crystallography, and Prof.
Tom Chang, who has been a fountain of knowledge for my synthetic chemistry work. Lastly, I
would like to thank my colleagues in the Hengge Lab who have been a constant presence in the
lab, late hours and early mornings – it has been a pleasure working with you.
I would like to thank my parents for being great role models and timely inspiration. I
would like to give special and heartfelt thanks to my wife, Padmashri Suresh, who has been a
constant companion through highs and lows, and a great source of inspiration and strength.

Alok G. Shenoy

vii
CONTENTS

Page
ABSTRACT........................................................................................................................................ iii
PUBLIC ABSTRACT ........................................................................................................................... iv
ACKNOWLEDGMENTS ..................................................................................................................... vi
CONTENTS ...................................................................................................................................... vii
LIST OF TABLES ................................................................................................................................ ix
LIST OF FIGURES ............................................................................................................................... x
CHAPTER

1. INTRODUCTION ............................................................................................................ 1
Classification of Dephosphorylating Enzymes .................................................. 1
Phosphothreonine lyases released by Salmonella & Shigella........................... 2

2. LITERATURE REVIEW .................................................................................................... 4
OspF classified as a Dual specificity phosphatase............................................. 4
Structural and mutational studies show that OspF and SpvC dephosphorylate
threonine residue......................................................................................... 7
Structural data on phosphothreonine lyase class of enzymes is limited. ....... 14
The mechanism of the elimination reaction is yet to be determined. ........... 16

3. MATERIALS AND METHODS ....................................................................................... 20
Genomics – cloning and site directed mutagenesis ....................................... 20
Purification of the enzymes SpvC and SpvC H106N........................................ 22
Enzymology – assay protocol and materials ................................................... 24
Crystallization of SpvC WT & H106N mutants ................................................ 25
Data collection and processing ....................................................................... 26

4. RESULTS ...................................................................................................................... 28
Crystallography ............................................................................................... 28

viii
Structural aspects of SpvC WT (4HAH) as compared to the previously
published structure (2Z8M) ....................................................................... 28
Structural aspects of SpvC H106N (PDB ID: 4H43).......................................... 32

5. DISCUSSION ................................................................................................................ 38
6. CONCLUSION .............................................................................................................. 42
REFERENCES ................................................................................................................................... 44

ix
LIST OF TABLES

Table

Page

1. Published crystal structures of enzymes comprising the phosphothreonine lyase class.
Shown are the PDB ID's, the resolution of the structures, the space group and the
ligands. .............................................................................................................................. 16

2. Primers used to clone spvC into the prk793 variant and carry out site directed
mutagenesis, mutating H106 to N106. The mutation (H106N) highlighted in red. ......... 21

3. Data collection and refinement statistics for SpvC WT. ................................................... 29
4. Average B factors of side chains and backbone of several residues of SpvC H106N (4H43)
that form the movable loop. It is seen that the residues, which form the loop, have high
b-factors as compared to the overall b-factor of the protein (46.9). ............................... 35

x
LIST OF FIGURES

Figure

Page

1. . Immunoblot assay used to identify the substrate of OspF.6 It was noted that the WT
induced activation of the MEK1 kinase, but the subsequent activation of Erk was absent
as detected by western blot using antibodies specific to phosphorylated MEK1 and Erk.
The remaining pathways were unaffected. ........................................................................ 5
2. Immunoblot shows that OspF is inhibited by Vanadate. Also seen is a decrease in
intensity of the phosphothreonine bands, even in presence of the inhibitors, implying
OspF catalyzes dephosphorylation of both threonine and tyrosine residues. ................... 6
3. A stereo view image of the picomolar inhibitor okadaic acid bound to PP1. The key
residues involved in binding of the inhibitor to the protein are labeled.10 As seen,
okadaic acid forms several H-bonds to various active site residues. ................................. 7
4. Mass Spectra indicating the loss of 98 Da as shown by Shao et al.7 The 98Da could not be
attributed to dephosphorylation by either a PTP or a DuSP. ............................................. 8
5. NMR spectra comparing peptide isolated following incubation with SpvC and a control
experiment lacking the enzyme. The vinylic signal has been attributed to ßmethyldehydroalanine.11 .................................................................................................... 9
6. Reaction mechanism put forth by Shao et al. An elimination reaction resulting in a loss
of inorganic phosphate (H2PO4- - 97 Da) and a proton (1 Da) which is abstracted from
the alpha carbon atom...................................................................................................... 10
7. Ligand-free structure of spvC WT (PDB ID: 2P1W) showing a tertiary structure similar to
a cupped hand. ................................................................................................................. 10
8. Electrostatic potential surface of SpvC WT with synthetic peptide (PDB ID: 2Q8Y). Pocket
A & Pocket B are two highly electropositive pockets that bind the phosphothreonine and
phosphotyrosine respectively. .......................................................................................... 11
9. Immunoblot assay of WT OspF and various mutants with Erk2 substrate. An alanine
screen was used to identify key catalytic residues.8 It was seen that K102, H104 and
K134 were inactive or extremely slow in catalyzing the reaction. ................................... 12
10. In-vitro interactions between recombinant Erk and OspF WT and OspF mutants. 3 and 5
are inputs and pull-down respectively for OspF WT, Lane 6-8 and 11-13 are input and
pull-down of OspF mutants K102R, H104A, K134A respectively.8 Pull-down shows that
the mutants bind to the substrate with similar affinity as the wild type. ........................ 13
11. Stereo view of SpvC K136A, shown in light blue, bound to phosphopeptide, shown in
orange, PDB ID: 2Q8Y. ...................................................................................................... 14

xi
12. Proposed reaction mechanism of phosphothreonine lyase class of enzymes. The K136
behaves as the catalytic base that abstracts the proton followed by the H106 that
donates a proton to the leaving phosphate group. .......................................................... 15
13. Sequence alignment of SpvC, VirA, OspF and Edwardsiella putative virulence protein
shows highly conserved residues (marked by ‘*’), specifically the catalytic acid H106,
base K134 and several residues involved in binding of substrate .................................... 15
14. Possible mechanisms for elimination reactions shown herein schematically. Concerted
(14.1), E1cB (14.2) and E1 (14.3) shown herein with phosphoester as starting material
resulting in vinylic product and inorganic phosphate as products. .................................. 18
15. Tertiary structure of SpvC WT, PDB ID 2Z8M in purple, when compared to our structure
of ligand-free SpvC WT, 4HAH in teal, shows that the structures are very similar, with a
RMSD of 0.16 for 215 residues. ........................................................................................ 30
16. Comparisons of the positions of the active site residues of SpvC WT in the structure
4HAH (teal) obtained in this work, compared with a previously reported structure,
2Z8M, in purple. It is clearly seen that the residues from the two structures superimpose
each other. ........................................................................................................................ 31
17. pY binding pocket residues compared between structures obtained through this work
against previously published structures. Overlaid above are 4HAH, in teal, and 2Z8M, in
purple. ............................................................................................................................... 32
18. Shown above the structural alignment of SpvC WT (4HAH), in teal, on SpvC H106N
(4H43) in green. The RMSD for 3D overlap of the two structures for 215 residues is 0.33.
.......................................................................................................................................... 33
19. Active site of SpvC H106N (PDB ID 4H43), in green, structurally aligned to SpvC WT (PDB
ID: 4HAH), in teal. The mutation H106  N106 has been labeled. ................................. 34
20. Recognition site of SpvC H106 (PDB ID: 4H43), in green, aligned with SpvC WT (PDB ID:
4HAH), in teal. This site is known to bind to the phosphorylated tyrosine on the
substrate. Residue E215 is displaced by 1.8 Å, attributed to the mobile loop it is a part
of. ...................................................................................................................................... 34
21. The movable loop of ligand-free SpvC WT (4HAH), in teal, aligned to SpvC K136A (2Q8Y)
in light purple, with substrate bound, in orange. Upon substrate binding the R220
carrying loop changes its conformation to the closed form, such that the R220 is placed
in proximity to the phosphothreonine residue (P219) of the substrate. The change also
positions E215 in close proximity to the amide carbonyl of the substrate backbone. .... 36
22. The movable loop carrying the R220 and E215 residues compared between the
structures of SpvC WT shown in light blue and the SpvC H106N, shown in green.
Residues 200 to 225 compared using SSM 27a indicated a Q-score of 0.90 for all 26
residues. ............................................................................................................................ 37

CHAPTER 1
INTRODUCTION

This report presents work on the investigation of mechanistic aspects of the reaction
carried out by effector protein Salmonella plasmid virulence C (SpvC) with the aid of x-ray
crystallography. SpvC, an effector protein, catalyzes an elimination of phosphate from
phosphorylated MAPK enzyme Erk2.

1.1

Classification of Dephosphorylating Enzymes
Phosphorylation and dephosphorylation are universal mechanisms employed by

biological systems to activate or deactivate enzymes. Addition (phosphorylation) and removal
(dephosphorylation) of phosphate moiety at cytoplasmic pH require catalysis by enzymes.
Enzymes that carry out phosphorylation can be broadly classified as kinases. Enzymes that
dephosphorylate can either be classified as phosphatases or phosphothreonine lyases.
Phosphatases refer to a class of enzymes that catalyze the dephosphorylation of the
substrate by cleavage of the oxygen-phosphorus bond. This results in formation of an enzymephosphate complex and the release of the substrate carrying a free hydroxyl group. The enzyme
phosphate complex breaks down in the following step to release inorganic phosphate and
regeneration of the enzyme active site.
The phosphothreonine lyase class of enzymes is a set of effector proteins released by
various pathogens like Salmonella and Shigella. This class presently comprises of SpvC, OspF,
and VirA. These effector proteins are known to directly aid the virulence of the pathogens. The
activity of these enzymes involves the disruption of the MAPK pathway, preventing the
expression of chemokine interleukin-8. Host cells use this chemokine to trigger the immune
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response against the invading pathogen. The lack of interleukin-8 allows the pathogen to
proliferate almost without detection through the host intestinal epithelial cells.

1.2

Phosphothreonine lyases released by Salmonella & Shigella
These pathogens are mainly attributed with causing dysentery and are considered a

growing threat to humans due to fast developing antibiotic resistant strains. The past few years
have seen over 35 widespread outbreaks of salmonellosis in U.S.A. alone,1 and affecting over
one billion people worldwide.2
Salmonella carries 5 genes on loci named: salmonella plasmid virulence (spv). The
proteins expressed by these genes, namely spv R, A, B, C, and D, have been attributed to aid the
virulence of the pathogen. While the understanding of these proteins is limited, it has been
established that SpvB and SpvC are directly responsible for the post invasion virulence of
Salmonella.3
Shigella releases over 30 different effector proteins, of which the function of about five
proteins are known.4 Of the proteins released, some have been classified under ‘Outer shigella
protein’ (Osp).5 OspF is a protein released by Shigella, which is homologous to SpvC from
Salmonella with over 70% sequence similarity.
The functions of these enzymes were discovered recently and were initially mistaken to
be dual specificity phosphatases (DuSP),6 and later correctly classified as phosphothreonine
lyases.7 Given that these enzymes are essential for the virulence of the pathogen,
phosphothreonine lyases form an important drug target. The mechanism of catalysis and the
transition state structure is often used in rational drug development. The mechanism by which
phosphothreonine lyases catalyze the elimination of phosphate is unknown. Our objective has
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been to decipher the mechanism using analytical tools like deuterium isotope exchange and xray crystallography.
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CHAPTER 2
LITERATURE REVIEW

The phosphothreonine lyase class of enzymes is a recently discovered set of enzymes.
Arbibe et al.

6

initially classified these enzymes as dual specificity phosphatases. Li et al.

7-8

correctly deciphered the activity of OspF and SpvC, and classified these as phosphothreonine
lyases. The results and conclusions of these publications are discussed herein.

2.1

OspF classified as a Dual specificity phosphatase
Arbibe et al. 6 were the first group to successfully identify the substrate of
OspF. Based on their experimental results, the authors concluded that OspF is a
dual specificity phosphatase (DuSP) that dephosphorylates both tyrosine and
threonine residues on Erk2. Some of their key conclusions are summarized below.

2.1.1. Erk2 identified as the substrate of OspF
To identify the role of OspF in vivo, the authors incubated HeLa cells with the wild
type (WT) and non-virulent (–VP) strains of shigella in separate experiments. Antigens
specific to MEK1, Erk, c-Jun and their phosphorylated form pMEK1, pErk, pc-Jun
respectively were used to analyze the pool of proteins extracted from the HeLa cell s.
From the western blot obtained, shown in Figure 1, the authors concluded the
following:


Blot showed presence of inactive MEK1, and a gradual increase in the dually
phosphorylated pMEK1 over time. The WT strain induced the activation of
MEK1 to pMEK1

5


Although MEK1 was phosphorylated, Erk2 remained inactive over 180
minutes. Other pathways involving the activation of NF-kB activation
remained unaffected.

Figure 1. . Immunoblot assay used to identify the substrate of OspF.6 It was noted that the WT
induced activation of the MEK1 kinase, but the subsequent activation of Erk was absent as
detected by western blot using antibodies specific to phosphorylated MEK1 and Erk. The
remaining pathways were unaffected.

This led them to believe that OspF was able to deactivate Erk2, thus altering the factors affecting
the transcription of genes involved in immune response.

2.1.2. OspF classified as dual specificity phosphatase
The MAPK enzyme Erk2 has two phosphorylated residues in its active state –
phosphotyrosine and phosphothreonine. To identify the specificity of OspF, the authors used
immunoblot assays coupled with inhibition studies. They incubated the enzyme with its
substrate Erk2 in presence of two inhibitors :


Vanadate – an inhibitor of protein tyrosine phosphatases.9



Okadaic acid – a picomolar inhibitor of serine/threonine phosphatase.10
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These were then subjected to Western Blot, shown in Figure 2, with antigens specific to Erk2,
Erk2 with phosphorylated tyrosine (pY) and Erk2 with phosphorylated threonine (pT).

Figure 2. Immunoblot shows that OspF is inhibited by Vanadate. Also seen is a decrease in
intensity of the phosphothreonine bands, even in presence of the inhibitors, implying OspF
catalyzes dephosphorylation of both threonine and tyrosine residues.

Based on the intensity of the bands of pT and pY, the authors concluded that OspF was
inhibited by vanadate, implying specificity for pY. They also observed a decrease in intensity of
the pT bands in presence of either inhibitor. This led them to conclude that OspF was
dephosphorylating both threonine and tyrosine residue, and hence classified it as a dual
specificity phosphatase.
In the course of our literature review, we find that Arbibe et al. 6 failed to consider the
significance of the pT-XAA1-pY motif, which was addressed by another research group discussed
later. The skewed conclusion could be attributed to several factors, e.g. the crystal structure of
okadaic acid bound to PP1, shown in Figure 3. Crystal structure, Figure 3A, indicates the
positions of various active site residues with respect to the inhibitor okadaic acid. A schematic
view of the hydrogen bonds is shown in Figure 3B, indicating all hydrogen bonds between the
protein and the inhibitor.
The OspF lacks any of the conventional sequence motifs of phosphatases. This aspect of
OspF would account for the lack of inhibition by okadaic acid. This result combined with the
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inhibition of OspF by vanadate points towards phosphotyrosine being essential in binding of the
substrate.

Figure 3. A stereo view image of the picomolar inhibitor okadaic acid bound to PP1. The key
residues involved in binding of the inhibitor to the protein are labeled. 10 As seen, okadaic acid
forms several H-bonds to various active site residues.

2.2

Structural and mutational studies show that OspF and SpvC dephosphorylate
threonine residue
Li et al.7-8 addressed the shortcomings of the previous publications by using a

biochemical approach to determine the activity and the specificity of OspF and SpvC. The group
used a combination of analytical techniques including mass spectrometry (MS), nuclear
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magnetic resonance (NMR) and X-ray crystallography to study the protein and the substrate.
Based on their results, reviewed in this section, the authors concluded that OspF and SpvC
catalyze the cleavage of phosphate by a unique elimination reaction without the involvement of
any co-factors.

2.2.1

OspF and SpvC dephosphorylate phosphothreonine residue on Erk2
The authors used MS to analyze the product from the reaction between OspF and a

synthetic phosphopeptide. Their results, shown in Figure 4, indicated a loss of 98 Da.
Dephosphorylation by a phosphatase would result in a loss of 78 Da, hence dephosphorylation
of both pY and pT would result in a decrease of 156 Da. The mass spectra also showed that the
phosphate group on tyrosine was intact, implying that these enzymes were specifically targeting
the phosphothreonine residue on the substrate.

Figure 4. Mass Spectra indicating the loss of 98 Da as shown by Shao et al.7 The 98Da could not
be attributed to dephosphorylation by either a PTP or a DuSP.

To identify the product formed post reaction they subjected the reaction product to
NMR spectroscopy. Then NMR spectrum of the product (Figure 5), when compared to that of
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the starting material, showed a new vinylic signal. Kuipers et al.11 had attributed this signal to
methyl dehydroalanine, formed by dehydration of threonine.

Figure 5. NMR spectra comparing peptide isolated following incubation with SpvC and a
control experiment lacking the enzyme. The vinylic signal has been attributed to ßmethyldehydroalanine.11

To test if their conclusion about the new vinylic product was correct, they incubated the
product with a kinase. It was seen that the synthetic peptide was not rephosphorylated on the
threonine residue.
Based on the evidence gathered, they concluded that SpvC/OspF was irreversible
dephosphorylating Erk2 by a unique elimination mechanism. Their proposed mechanism is
schematically shown in Figure 6. A general catalytic base abstracts a proton from the alpha
carbon of the threonine resulting in the formation of a double bond and the cleavage of the
carbon-oxygen bond linking threonine to the phosphoester.
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Figure 6. Reaction mechanism put forth by Shao et al. An elimination reaction resulting in a
loss of inorganic phosphate (H2PO4- - 97 Da) and a proton (1 Da) which is abstracted from the
alpha carbon atom.

2.2.2

X-ray crystallography and kinetic studies point to K136 and H106 as the catalytic
acid and base of SpvC, respectively
To identify the key residues involved in the catalysis and the role of the phosphotyrosine

on the substrate, the authors carried out crystallographic studies. X-ray crystallography showed
a unique tertiary structure of SpvC, shown in Figure 7.

Figure 7. Ligand-free structure of spvC WT (PDB ID: 2P1W) showing a tertiary structure similar
to a cupped hand.
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The structure resembled a cupped hand with two highly electropositive centers on the
concave side. A structure with a synthetic peptide bound showed that the two phosphorylated
resides bound to these electropositive cavities, as shown in Figure 8.

Figure 8. Electrostatic potential surface of SpvC WT with synthetic peptide (PDB ID: 2Q8Y).
Pocket A & Pocket B are two highly electropositive pockets that bind the phosphothreonine
and phosphotyrosine respectively.

The group used an alanine screen to identify the role of the residues present in the two
electropositive pockets. Residues of OspF were mutated to alanine or arginine one by one and
the activity of these mutants were tested with Erk2 substrate. Using Western Blot and antigens
specific to Erk2 and pT-Erk2, the authors identified the specific mutants that were inactive or
extremely slow to catalyze the reaction. The blot obtained by them, shown in Figure 9, showed
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that the mutants K102R, H104A and K134A were inactive. The corresponding residues of SpvC

Figure S5

were identified as K104, H106 and K136.

Figure 9. Immunoblot assay of WT OspF and various mutants with Erk2 substrate. An alanine
screen was used to identify key catalytic residues.8 It was seen that K102, H104 and K134 were
inactive or extremely slow in catalyzing the reaction.

To identify if the mutations had resulted in loss of binding affinity, the authors carried
out a Maltose Binding Protein pull-down assay. A fusion protein of Maltose Binding Protein
(MBP) with Erk2 was purified. The purified MBP-Erk2 was immobilized onto amylose beads.
These beads were then incubated with OspF. The beads were then washed extensively, and the
flow-through of these washes was subjected to SDS-PAGE and coomassie staining to
qualitatively detect if OspF was bound to the MBP-Erk on the beads. Results obtained by the
group are shown in Figure 10. Lane 3 and 5 are inputs and pull-down for wild type OspF
respectively. Lane 6-8 and Lane 11-13 are inputs and pull-down for OspF K102R, H104A and
K134A mutants, respectively.
Based on the results obtained from the MBP pull down, they concluded that these
mutants were capable of binding to the substrate. To identify the roles of these residues in
catalysis the authors carried out kinetic studies to identify the pH rate profile. They found that
the WT SpvC shows a bell shaped pH rate profile with an optimum of pH 8.5.

Fig. S5. Mutation analysis of the phosphothreonine lyase activity of OspF. (A) Equal
amounts of wild type or indicated mutant OspF proteins were added in each reaction.

Figure S2
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Figure 10. In-vitro interactions between recombinant Erk and OspF WT and OspF mutants. 3
and 5 are inputs and pull-down respectively for OspF WT, Lane 6-8 and 11-13 are input and
pull-down of OspF mutants K102R, H104A, K134A respectively.8 Pull-down shows that the
mutants bind to the substrate with similar affinity as the wild type.

Fig. S2. Interaction between OspF and Erk2 in vitro and in 293T cells.
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reaction. This, along with the mutational studies of the K104 and H106 residues, indicated that
the K136 residue behaves as the base. K136 abstracts the proton from the alpha carbon of
phosphothreonine. The K104 residue was deemed responsible for H-bonding with the substrate
12

backbone amide carbonyl, thus reducing the pKa of the proton on alpha carbon of
phosphothreonine.
The authors also determined a crystal structure of SpvC K136A bound to a synthetic
peptide. The peptide sequence derived from Erk2 contained the pT-XAA1-pY motif in the
sequence and was co-crystallized with the inactive SpvC K136A mutant. A stereo image of the
structure is shown in Figure 11.

14

Figure 11. Stereo view of SpvC K136A, shown in light blue, bound to phosphopeptide, shown
in orange, PDB ID: 2Q8Y.

Based on the peptide bound structure of SpvC K136A, the WT structure and the data
obtained by the group through mutational and kinetic studies, Shao et al. have proposed the
mechanism for the dephosphorylation carried out my OspF and SpvC, shown in Figure 12.

2.2.3

Structural data on phosphothreonine lyase class of enzymes is limited
A BLAST of the sequence of SpvC results in 4 proteins: SpvC (released by Salmonella

entrica); OspF (released by Shigella flexneri); VirA (released by Chromobacterium violaceum);
and FL6-60 - a putative virulence protein (released by Edwardsiella tarda). A multi-sequence
alignment of these proteins is shown in Figure 13.
Structures obtained by various groups using X-Ray crystallography have been deposited
in the Protein Data Bank. A summary of the structures obtained for members of the
phosphothreonine lyase class of proteins is given in Table 1.
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Figure 12. Proposed reaction mechanism of phosphothreonine lyase class of enzymes. The
K136 behaves as the catalytic base that abstracts the proton followed by the H106 that
donates a proton to the leaving phosphate group.

Figure 13. Sequence alignment of SpvC, VirA, OspF and Edwardsiella putative virulence protein
shows highly conserved residues (marked by ‘*’), specifically the catalytic acid H106, base
K134 and several residues involved in binding of substrate
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Table 1. Published crystal structures of enzymes comprising the phosphothreonine lyase class.
Shown are the PDB ID's, the resolution of the structures, the space group and the ligands.
Protein

PDB ID

Resolution (A)

7

2P1W

2.30

P42 21 2

None

SpvC WT

12

2Z8M

2.00

P21 21 21

None

SpvC WT

12

2Z8N

1.80

P21

Sulfate Ion

SpvC WT

12

2Z8O

2.40

P41 2 2

Tartaric Acid

12

2Z8P

1.80

P21 21 21

Dually phosphorylated synthetic peptide

7

2Q8Y

2.0

P21 21 21

Dually phosphorylated synthetic peptide

SpvC WT

SpvC K136A

SpvC K136 A

Space group

Ligand

OspF WT

13

3I0U

2.70

P41 21 21

(4S)-2-Methyl-2,4-Pentanediol

VirA WT

14

3B06

1.40

P21

None

2.2.4

The mechanism of the elimination reaction is yet to be determined
While the efforts of the above mentioned groups have allowed us to decipher the

activity of these enzymes, what is yet to be answered in the mechanism used by these enzymes
is uncertain. Previous studies of elimination reactions catalyzed by enzymes have shown that
the preferred mechanism is E1cB, involving the formation of a carbanion intermediate.
Considering the novelty of these enzymes and the reaction catalyzed by these enzymes,
SpvC/OspF may or may not follow this mechanism; hence other possibilities, shown in Figure 14,
have to be considered.
Enzyme catalysis involving elimination has been observed in various biological systems.
One such enzyme is serine/threonine ammonia lyase, commonly known as serine/threonine
dehydratase. These are classified as PLP-dependent enzymes due to the involvement of the PLP
co-factor in catalysis of the reaction. This is unlike phosphothreonine lyases, wherein the
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enzyme does not utilize any co-factor to dephosphorylate the substrate. Nonetheless, the
reactions catalyzed by both enzyme classes involve the abstraction of a proton to form a vinyl
group along with elimination of a leaving group. In case of the serine/threonine dehydratase,
the leaving group is water.
β-Elimination can be carried out by any one of the mechanisms listed below:
1. Concerted – where in the proton abstraction and the phosphate elimination takes
place simultaneously, shown in Figure 14.1.
2. E1cB – Reaction involving formation of a carbanion by abstraction of proton, shown
in Figure 14.2. This reaction mechanism is inherently stepwise and two possibilities
arise:
i. E1cBR: The proton abstraction is reversible, which implies the
elimination of the phosphate is slow and hence the rate
determining step. This indicates that k-1 is comparable or higher
than k2. Hence the intermediate will pick up a proton to return to
the starting material.
ii. E1cBF: The proton abstraction is the rate-determining step,
following which the elimination of the phosphate occurs rapidly.
iii. This implies that k1 is significantly lower to k2, hence any
intermediate formed converts to product.
3. E1 – Where in the phosphate group leaves first creating a carbocation followed by
abstraction of the proton, shown in Figure 14.3.
In the case of concerted and E1cB mechanisms, it is possible that the elimination of the
phosphate is irreversible. In order to account for all possibilities we depict the reaction to be
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reversible. This report presents the body of work carried out to identify if this class of enzymes
follows an E1cB mechanism involving the reversible formation of a carbanion at the active site.
Analytical techniques like isotope exchange when coupled with crystal structures of the
protein concerned provide more details of the reaction involved.15 It is essential that the
mechanism of the beta-elimination be deduced so as to elucidate the transition state of the
substrate-enzyme complex. This, in turn will aid inhibitor design for the enzymes.

Figure 14. Possible mechanisms for elimination reactions shown herein schematically.
Concerted (14.1), E1cB (14.2) and E1 (14.3) shown herein with phosphoester as starting
material resulting in vinylic product and inorganic phosphate as products.

To determine if the enzymes use the E1cB mechanism, we chose to use deuterium
isotope exchange experiment. Deuterium isotope exchange experiments are used to identify the
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rate-determining step in multi-step reversible elimination reactions wherein proton abstraction
is involved. The incorporation of an isotopically labeled atom from the solvent into the substrate
is often used as a method to decipher the mechanism. We used this technique to identify
whether a carbanion intermediate is formed in the mechanism used by SpvC to catalyze the
elimination of phosphate. This involved carrying out the reaction in a deuterated solvent
followed by isolation of the substrate peptide. This peptide would undergo M.S. analysis to
determine incorporation of deuterium on the c-alpha carbon.
To carry out the above experiment, it was necessary that any carbanion intermediate
formed at the active site did not convert to the vinylic product. Creating a mutant that could not
protonate the leaving group would provide an enzyme in which any carbanion created at the
active site would revert back to its protonated state by equilibrating with the solvent. Thus we
chose the H106N mutant, which was earlier proven to be inactive.7 The H106N mutant lacked
the histidine that was determined to be the general acid, donating a proton to the leaving
phosphate group. The work presented herein involves structural studies of this mutant to
determine if the mutation resulted in structural perturbations that could account for the lack of
activity.
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CHAPTER 3
MATERIALS AND METHODS

3.1

Genomics – cloning and site directed mutagenesis
Dr. Feng Shao (of National Institute of Biological Sciences, Beijing, China) graciously

provided us with the plasmids for MBP-OspF and MBP-SpvC, containing a GST tag. SpvC was
cloned into a variant of prk793 vector such that the final sequence resulted in 10x histidine
tagged SpvC with TEV cleavage site in between.
The gene for SpvC was amplified to generate multiple copies of the original gene
sequence using the primers SpvC Forward (SF) and SpvC Reverse (SR), given in Table 2. These
primers also incorporated a TEV cleavage site before and a BAMHI restriction site at the end of
the SpvC sequence respectively. The product of this PCR was isolated using electrophoresis and
Qiagen QIAquick PCR kit. A second PCR was carried out to insert a KpnI restriction site upstream
of the TEV cleavage site. The PCR product was digested using KpnI and BamHI restriction
enzymes (Fermentas) and ligated into a modified prk793 vector containing 10xhistidine tag
upstream of the maltose binding protein (MBP) domain. The plasmid from this ligation – HisTEV-SpvC-prk793 (HP-SpvC) was purified using the protocol and materials provided in the
Qiagen QIAquick PCR Purification Kit (Qiagen).
The HP-SpvC plasmid was used to transform DH5-α strain of E-coli cells and plated on
sterilized agar media plates with ampicillin and chloramphenicol. These were incubated at 37˚C
overnight. Colonies from the plate were selected to inoculate 10mL aliquots of LB-media with
aforementioned antibiotics. These aliquots were placed in 37˚C shakers overnight. The cells
were pelleted and the plasmids extracted using the protocol and materials provided in QIAprep
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Spin Miniprep kit. The solution containing the plasmids was aliquoted into eppendorf tubes and
stored at -20˚C for future use.

Table 2. Primers used to clone spvC into the prk793 variant and carry out site directed
mutagenesis, mutating H106 to N106. The mutation (H106N) highlighted in red.
Primer Name
SpvC Forward (SF)

Primer Sequence (5’ to 3’)
GAAAACCTGTATTTTCAGGGCATGCCCATAAATAGGCCTA
ATC

SpvC Reverse (SR)

CGCGGATCCTTACTCTGTCATCAAACGATAAAACGG

SpvC KpnI (SKF)

CGGGGTACCGAAAACCTGTAT

SpvC SDM Forward
(SSF)
SpvC SDM Reverse
(SSR)

GCCGGTGACAAGTTCAACATCAGTGTGCTCAGG
CCTGAGCACACTGATGTTGAACTTGTCACCGGC

Description
Forward primer used to amplify
the SpvC gene.
Reverse primer used to amplify
the SpvC gene.
Primer used to insert the KpnI
restriction site.
Forward primer used in site
directed mutagenesis
Reverse primer used in site
directed mutagenesis.

The plasmids were used to transform BL-21 codon+ strain E-coli cells. Sterilized baffled
flasks containing 10mL of LB media, containing 100mg/mL of ampicillin and chloramphenicol
each, were inoculated using the transformed cells. These were shaken at 37˚C for 18 hours until
an optical density at 600nm (OD600) of 1.5 to 1.8 was achieved. These growths were then mixed
with 50% sterilized glycerol solution, in 4:1 ratio, and frozen at -80˚C for future use.
The mutant SpvC H106N was created by site directed mutagenesis (SDM) using the
protocol and materials provided in the Quick Change Lightning Kit (Agilent Technologies). The
vectors SSF and SSR were used to insert the mutation. The plasmids were purified by Qiagen
QIAquick PCR kit. Copies of the HP-SpvC-H106N plasmid were created using E-coli DH5-α cells,
isolated and sequenced to confirm correct mutation.
The plasmids were used to transform BL-21 codon+ strain E-coli cells with ampicillin and
chloramphenicol resistance. Sterilized baffled flasks containing 10mL of LB media, containing
100mg/mL of ampicillin and chloramphenicol each, were inoculated using the transformed cells.
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These were shaken at 37˚C for 18 hours until an optical density at 600nm (OD 600) of 1.5 to 1.8
was achieved. These growths were then mixed with 50% sterilized glycerol solution, in 4:1 ratio,
and frozen at -80˚C for future use.

3.2

Purification of the enzymes SpvC and SpvC H106N
Four liters of 2x YT media was prepared in baffled flasks and sterilized by autoclaving.

This was then inoculated E-Coli BL21 codon+ strain, transformed with the HP-SpvC-WT or HPSpvC-H106N plasmid. The broth was shaken at 37˚for up to 16 hours such that the optical
density of the broth was noted at 1.5 OD600.
The broth was then induced with stock solution of 100 m

sopropyl β-D-1-

thiogalactopyranoside (IPTG) such that final concentration of IPTG was 1mM. At this point the
broth was moved from 37˚C shakers to room temperature (r.t.) shakers and left overnight (up to
12 hours) to produce a good yield of the protein. The cells were then pelleted by centrifugation
in a Fiberlite* F10-4x1000 LEX Rotor (Thermo Scientific), mounted on Sorvall RC-6 Plus
Superspeed centrifuge, at 5000 rpm (9800 g) and stored at -80˚C for future use. The buffer
solutions used to purify His-SpvC were prepared using Nano-purified water (desalinated water)
and adjusted to the required pH at 4˚C. Each buffer was filtered through a

ilipore 20µm filter

before use.
The frozen stock of cell from -80˚C was thawed and warmed to 0˚C and re-suspended in
the lysis buffer (pH 8.0 tris(hydroxymethyl)aminomethane (Tris-HCl) 20mM, Imidazole 20mM,
NaCl 500mM, Glycerol 5% and ß-Mercaptoethanol 5mM) along with protease inhibitors
aprotinin, leupeptin and pepstatin. The cells were broken by sonication and the debris was
pelleted by centrifugation in SS-34 rotor (mfg. Thermo Scientific) mounted on a Sorvall RC-6 Plus
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Superspeed Centrifuge, at 20,500 rpm (50,228 g) for 45 minutes. The supernatant was then
incubated with 15 mL nickel resin (GE Nickel Sepharose High Performance) for a period of 2
hours at 4˚C and placed on a rotary shaker. This was followed by separating the resin from lysate
by filtration and re-suspension of the nickel resin in lysis buffer. The resin was washed with 4 – 6
bed volumes of lysis buffer to ensure removal of non-specifically bound proteins and debris.
The elution was carried out by running a gradient of elution buffer (pH 8.0, Tris-HCl
20mM, Imidazole 500mM, NaCl 500mM, Glycerol 5% and ß-Mercaptoethanol 5mM) mixed with
decreasing amounts of lysis buffer over a span of 120mL. The fractions were selected based on
purity of the protein contained, determined by SDS-PAGE. The fractions were combined and
loaded into 10kD dialysis tubing, which was suspended in TEV-cleavage buffer (pH 8.0, Tris-base
50mM, EDTA 0.5mM, Dithiothreitol (DTT) 1mM, Glycerol 5%), for 4 hours. The buffer (TEVcleavage) was changed at regular intervals to eliminate imidazole from the combined fractions.
TEV-protease, an enzyme efficient in cleaving fusion proteins at sites containing the EXaa-Xaa-Y-Xaa-Q-(G/S) sequence, was used to cleave the His-tag from SpvC. During the cloning
stage, this cleavage site was inserted at the N-terminus of the protein that the final SpvC
sequence was left with minimal residues from the tag and the cleavage site. The dialysis tube
containing the combined fractions and TEV-protease was incubated in the TEV-Cleavage buffer
for approximately 8 hours. Completion of the cleavage was checked using SDS-PAGE.
After the total cleavage of the fusion protein, it was necessary to separate the cleaved
His-tag and TEV protease from SpvC. The contents of the dialysis tube were incubated with clean
Ni-resin for 2 hours. SpvC, now in the flow through, was collected along with the washing of the
Ni-Resin. SDS-PAGE was carried out to confirm the absence of the cleaved His-tag in the flowthrough.
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The pure SpvC was then concentrated using 10kD conical tube concentrators. The final
concentrate, 3-5 mL of clear solution containing pure SpvC, was used for 120mL Superdex GelFiltration. The gel-filtration was carried out using the Superdex buffer (pH 8.5, Tris-HCl 50mM,
NaCl 150mM, Glycerol 5%), and the fractions collected. This provided SpvC in purity exceeding
95%, which was confirmed by SDS-PAGE.
SpvC H106N mutant was purified using the same protocol as the WT. It was observed
that the purification of the mutant using the above protocol afforded similar yields and purity
exceeding 95%, confirmed using SDS-PAGE.

3.3

Enzymology – assay protocol and materials
Earlier work

7

had shown that the histidine residue at position 106 functions in the

catalytic reaction as the acid, donating a proton to the leaving inorganic phosphate moiety. We
first tested the activity of the WT enzyme to confirm the integrity of the purified protein and to
test the optimum reaction conditions. To do this, we incubated the enzyme at various pH values
with a synthetic peptide of the sequence H-Glu-Met-pThr-Gly-pTyr-Val-Ala-OH. The release of
phosphate was measured by using a colorimetric assay.16
The peptide was dissolved in the reaction buffer containing 50 mM Tris and 1 mM DTT
pH 8.5. The same buffer was used to prepare a series of peptide dilutions in the range of 5-210
µM. 90 µL of substrate peptide were aliquoted in the wells of flat bottom 96 well plate (Costar,
Fisher) and 10 µL of SpvC WT were added to the final concentration of 9.4 nM to start the
reaction. After 60 seconds the reaction was quenched by addition of 230 µL of malachite green
assay reagent. After 15 minutes the absorbance at 625 nm was measured and converted to
inorganic phosphate concentration via a standard curve obtained using a phosphatate standard
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diluted with reaction buffer. Blank readings obtained from wells to which 10 µL of water were
added in place of the enzyme were subtracted to account for non-enzymatic phosphate release.
Calculated rates were plotted against peptide concentrations and fitted to the MichaelisMenten equation to obtain kinetic parameters kcat and KM of 3.2 ± 0.16 sec-1 and 52 ± 6.0 µM,
respectively.
Having confirmed the activity of the WT, site directed mutagenesis was carried out
successfully resulting in the H106N – an inactive mutant of SpvC. The purification strategy for
the H106N mutant was same as the WT, resulting in protein of 95% purity and higher.
To test for the E1cB mechanism, a deuterium isotope exchange experiment was carried
out. The synthetic peptide was incubated with SpvC H106N at pH 8.5 overnight in deuterated
water based buffer. This was then treated with trifluoroacetic acid to denature and precipitate
the enzyme. An eppendorf concentrator 10 kDa pore size was used to remove the enzyme from
the quenched reaction mixture. The filtrate was then lyophilized overnight and then
resuspended in H2O. The same was carried out for a blank, wherein no enzyme was added to the
reaction mixture. M.S. analysis of the isolated peptide showed that the experiment did not
result in deuterium exchange on the α-carbon atom of the phosphorylated threonine.

3.4

Crystallization of SpvC WT & H106N mutants
The purified SpvC WT was first concentrated to 30 mg/mL (extinction coefficient of

23045 cm-1 M-1 calculated using ProtPram of Expasy Tools
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), confirmed by Micro-Volume Full-

Spectrum Fluorospectrometer (Mfg. by NanoDrop Products). This concentrated protein was
then used to manually set up vapor diffusion sitting drop trays by hand. A grid of 6x4 with
varying concentrations of PEG and Ammonium Chloride was created to screen for the optimum
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conditions to crystallize the WT protein. The trays were set and maintained at room
temperature (289 K). Crystals appeared after a week and were of square bi-pyramidal shape.
These were frozen using liquid nitrogen after soaking the crystals in the well conditions
containing increasing quantity of glycerol (up to 15%). The optimum conditions for the WT that
afforded reproducibility were determined as following: Protein to Well Condition ratio of 1:1,
20% PEG 3350 (a 50% w/v solution), 0.1M Ammonium Chloride (1M stock solution).
The mutant SpvC H106N was concentrated to 14 mg/mL of solution. A robot was used
to screen for various conditions using kits produced by various companies like Hampton
Research, Molecular Dimensions, etc. The Morpheus Protein Crystallization Screen18
manufactured by Molecular Dimensions provided the conditions required to crystallize the
protein, which was further optimized to afford reproducibility. Crystals of monoclinic shape
were obtained which were frozen using liquid nitrogen after soaking the crystals in the well
conditions containing increasing quantity of glycerol (up to 15%). The conditions were
determined to be as follows: Protein to Well Condition ratio of 3:1, 20% PEG 550 MME, 10% PEG
20000 (30% w/v solution), 0.1M Amino Acids Mix (1M stock solution mfg. by Molecular
Dimensions), 0.1M Buffer System 1 18 at pH 6.5.

3.5

Data collection and processing
Data for the WT crystal were obtained by using home source generator and detector

(Rigaku RU-200/Raxis IV++). Data was indexed and processed using d*TREK19 in the suite Crystal
Clear. Molecular replacement was carried out using AutoMR / Phaser
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of the Phenix suite.21

The search model was the 1.4Å structure of SpvC (Protein Data Bank (PDB) entry 3BO6)
complexed with sulfate ion. Refinements were carried out with Phenix Refine tool.22 The data
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for the H106N crystal was collected at Stanford Synchrotron Radiation Lightsource (SSRL). Data
processing was carried out on SSRL servers followed by molecular replacement using AutoMR /
Phaser

20

of the Phenix suite.21 Refinement was carried out using Phenix Refine.22 TLS

parameters were selected using the TLS Motion Determination server.23 In both cases Coot24
and MolProbity25 were used to carry out model building and validation. The crystallographic
data and the statistics are given in Table 5 (SpvC WT) & Table 6 (SpvC H106N). All figures
depicting SpvC crystal structures were prepared using PyMol.26 The structures of SpvC WT and
H106N mutant have been submitted to PDB under the ascension IDs 4HAH and 4H43,
respectively.
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CHAPTER 4
RESULTS

4.1

Crystallography
The two structures obtained have been submitted to the Protein Data Bank (PDB) under

the ascension IDs 4HAH (SpvC WT) and 4H43 (SpvC H106N mutant). The wild type was
crystallized under conditions previously published,7 and then further optimized for
reproducibility. The SpvC H106N mutant was initially crystallized using Morpheus Protein
Crystallization Screen (mfg. Molecular Dimensions) with the aid of ARI Crystal Gryphon robot.
The two structures have been compared to previously published structures to determine the
structural integrity of the mutant. The statistical data for SpvC WT (4HAH) and SpvC H106N
(4H43) have been presented in Table 3.

4.2

Structural aspects of SpvC WT (4HAH) as compared to the previously published
structure (2Z8M)
The structure used to verify the integrity of the crystallized SpvC WT was a 2Å ligand-

free structure (PDB ID: 2Z8M).12 The structures were overlapped in PyMol26 to compare the
tertiary and secondary structures of the two ligand-free proteins. As shown in Figure 15, the
tertiary structure of the two proteins closely resembled each other in terms of positions of
loops, helices and β-sheets. PDBeFOLD27 was used to compare the structures by assessing the
overlap of the backbone and the side chains of all the amino acids present in each of the
structures. The result (RMSD = 0.16) is presented in terms of root mean square deviation
(RMSD). The lower the RMSD, the better the overlap of the two structures.
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Table 3. Data collection and refinement statistics for SpvC WT.
Values in brackets correspond to those in outer resolution shell.

Data Collection

SpvC WT

SpvC H106N

Beamline

Homesource

SSRL

Wavelength (Å)

1.5418

0.97591

Resolution Range (Å)

32 – 1.80

50 – 2.3

Outer Shell (Å)

1.86 – 1.80

2.38 – 2.30

Total

331429

405022

Unique

45887

35594

Average Redundancy

7.22 (4.35)

11.4 (11.5)

Mean I/ σ ( )

9.0 (2.5)

33.655 (4.4)

Completeness (%)

98.4 (86.8)

99.8 (99.5)

Rsym (%)

0.107 (0.485)

0.076 (0.614)

Space Group

P212121

P32

Unit Cell Dimensions (a, b, c) (Å)

64.53 71.91 106.49

70.989 70.989 142.972

0.1935 / 0.2310

0.1749 / 0.2161

Protein

3496

3478

Water

468

191

Protein

22.01

46.88

Water

30.91

47.3

0.007 / 1.024

0.007 / 0.979

Ramachandran Outliers (%)

0.00

0.0

Ramachandran Favored (%)

99

98.6

Rotamer Outliers (%)

0.5

0.52

PDB Entry

4HAH

4H43

No. of Reflections

Refinement
Rwork / Rfree (%)
Atoms in structure

2

Average B-factors (Å )

Root mean square deviation
bonds (Å) / angles (degrees)
Protein geometry
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Figure 15. Tertiary structure of SpvC WT, PDB ID 2Z8M in purple, when compared to our
structure of ligand-free SpvC WT, 4HAH in teal, shows that the structures are very similar, with
a RMSD of 0.16 for 215 residues.

A close inspection of the structure 4HAH compared to 2Z8M showed that crucial
residues important to catalysis are overlapping, as shown in Figure 16.
In addition to the catalytic site, SpvC has another binding pocket for the second
phosphoryl group (pY) of the enzyme’s native bis-phosphorylated substrates. The residues in
this pocket responsible for binding phosphotyrosine were also found to have retained their 3dimensional positions when compared to 2Z8M, as shown in Figure 17.
To support the structural analysis, a chemical assay was carried out to confirm the
ability of the purified enzyme to dephosphorylate the substrate. This was done using a
truncated peptide, containing the pT-XAA-pY motif, H-Q-M-pT-G-pY-V-A-OH. The enzyme on
incubation with the peptide at pH 8.5 resulted in release of inorganic phosphate, which was
detected using phosphomolybdate assay.16 Having confirmed the activity of the WT, we pursued
the crystallization of the H106N mutant, previously found to be inactive7 and used by us in a
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deuterium isotope exchange experiment designed to probe the chemical mechanism. Because
this experiment resulted in no deuterium isotope exchange, the goal of the structural study was
to investigate if the mutation resulted in structural perturbations that would prevent the ability
of the protein to bind to the substrate.

Figure 16. Comparisons of the positions of the active site residues of SpvC WT in the structure
4HAH (teal) obtained in this work, compared with a previously reported structure, 2Z8M, in
purple. It is clearly seen that the residues from the two structures superimpose each other.
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Figure 17. pY binding pocket residues compared between structures obtained through this
work against previously published structures. Overlaid above are 4HAH, in teal, and 2Z8M, in
purple.

4.3

Structural aspects of SpvC H106N (PDB ID: 4H43)
The H106N mutant has been reported previously, but to date no structure exists in the

Protein Data Bank. In order to correctly interpret the results of mechanistic investigations with
this mutant, an x-ray crystal structure of the protein was necessary. This would allow us to
determine if the mutation of the wild-type protein resulted in structural perturbations that
might affect the binding.
Sequencing confirmed the presence of the correct mutation following which the purified
enzyme was used to obtain crystals in sitting-drop experiments set up by hand. PDBeFOLD27
was used to compare this crystal structure, PDB ID 4H43, with the SpvC WT structure, PDB ID
4HAH. Calculations showed a RMSD of 0.33Å. Tertiary structures were compared in PyMol,26 as
shown in Figure 18.
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The mutant was aligned with the WT to compare the positions of active site residues, as
shown in Figure 19. The conclusion is that the mutation of the histidine residue on position 106
to asparagine does not affect the secondary or tertiary structure of the protein. This supports
the conclusions reported from the kinetic assay work that the lack of activity of SpvC H106N is
due to the mutation of the catalytic general acid, and not due to structural deformations
induced by the mutation.

Figure 18. Shown above the structural alignment of SpvC WT (4HAH), in teal, on SpvC H106N
(4H43) in green. The RMSD for 3D overlap of the two structures for 215 residues is 0.33.

The structural alignment of the WT and the H106N mutant was used to verify the
position of residues involved in the two pockets which bind the phosphorylated tyrosine and
threonine residues, shown in Figure 20. It was seen E215 was displaced by 1.8Å and R220 was
displaced by 1.4 Å. It has been determined that the H215 residue forms H-bonds with the
backbone of the substrate. This segment of the protein, a loop carrying the catalytically
important residue R220, seems to be extremely mobile with a high B-factor as compared to the
average B-factor of the whole structure.
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Figure 19. Active site of SpvC H106N (PDB ID 4H43), in green, structurally aligned to SpvC WT
(PDB ID: 4HAH), in teal. The mutation H106  N106 has been labeled.

Figure 20. Recognition site of SpvC H106 (PDB ID: 4H43), in green, aligned with SpvC WT (PDB
ID: 4HAH), in teal. This site is known to bind to the phosphorylated tyrosine on the substrate.
Residue E215 is displaced by 1.8 Å, attributed to the mobile loop it is a part of.

35
B-Factors provide a numerical representation of the electron density detected at
specific positions during the x-ray diffraction. High B-factor values imply high mobility of the
residues, hence providing a reduced electron density. A study of the B-factors of the residues
forming the R220 loop showed that the backbone and the side chains for the residues were
significantly higher than the average B-factor of 46.9, as shown in Table 5. Average B-factors
were calculated using StrucTools.28 This implies that the loop carrying R220 and E215 residues is
mobile.
Figure 21 shows that the loop carrying the two residues R220 & E215 undergoes a
conformational change upon binding of the substrate. The R220 residue forms H-bonds with the
phosphate moiety on the phosphothreonine of the substrate. The E215 backbone amide N-H
forms H-bonds with the carbonyl of the backbone amide of the phosphotyrosine of the
substrate backbone. The mobility of the loop allows a conformational change to occur upon
substrate binding, bringing the respective residues in close proximity.

Table 4. Average B factors of side chains and backbone of several residues of SpvC H106N
(4H43) that form the movable loop. It is seen that the residues, which form the loop, have
high b-factors as compared to the overall b-factor of the protein (46.9).
Residue (Amino Acid)

Side Chain

Backbone

215 (E)

78.74

61.28

216 (L)

78.11

77.0

217 (R)

78.79

89.45

218 (S)

108.54

104.64

219 (G)

0.0

108.75

220 (R)

115.83

100.50

221 (D)

105.99

86.25
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The respective positions of the movable loop in the WT and the H106N mutant are
compared in Figure 22. It is seen that they closely resemble each other. A comparison using
Secondary Structure Matching (SSM) 27a showed that residues of the two loops had a Q-Score of
0.90, implying a close overlap of the two loops.
The structures of SpvC WT (PDB ID 4HAH) and SpvC H106N (PDB ID 4H43) closely
resemble each other in the catalytic site, the pY binding site and the positions of the loop
carrying the R220 and E215 residues. The H106N structure shows a high mobility of the loop,
which we believe is responsible for the need for crystallization conditions different than that of
SpvC WT. No significant deformations to the structure of the SpvC are induced due to the H106N
mutation.

Figure 21. The movable loop of ligand-free SpvC WT (4HAH), in teal, aligned to SpvC K136A
(2Q8Y) in light purple, with substrate bound, in orange. Upon substrate binding the R220
carrying loop changes its conformation to the closed form, such that the R220 is placed in
proximity to the phosphothreonine residue (P219) of the substrate. The change also positions
E215 in close proximity to the amide carbonyl of the substrate backbone.
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R220

E215

Figure 22. The movable loop carrying the R220 and E215 residues compared between the
structures of SpvC WT shown in light blue and the SpvC H106N, shown in green. Residues 200
to 225 compared using SSM 27a indicated a Q-score of 0.90 for all 26 residues.
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CHAPTER 5
DISCUSSION

5.1 Results indicate the absence of a carbanion intermediate
The objective of the presented research was to provide structural information to assist
in the interpretation of kinetics and mutagenesis experiments about the type of mechanism
followed by phosphothreonine lyases. As described earlier, elimination reactions can take any
one of the several pathways – E1, E1cBR, E1cBF and concerted, mechanisms of which were
shown in Figure 14. The research presented herein seeks to support the findings of the
aforementioned deuterium isotope exchange experiment with structural data. The objective
behind the research was two-fold:


Determine the crystal structure of SpvC WT purified using a previously unpublished
protocol.



Purify the H106N mutant and determine the structures. Compare the structures of the
wild type (4HAH) and the H106N mutant (4H43) to previously published structure
(2Z8M), with the goal of determining if the mutation results in any structural
perturbation that might affect substrate binding or catalysis.
The comparison of the two structures against previously published active WT structures

allows us to verify the integrity of the proteins purified and crystallized in this study. The
inactivity of the H106N mutant may arise due the structural changes induced due to the
mutation, which might affect the binding of the substrate. This would result in the observed lack
of deuterium exchange at the expected C-α, thus giving us a false positive result. In addition, the
previously reported kinetic experiments with this mutant concluding that H106 is the catalytic

39
general acid would be invalidated if significant structural perturbations were found. Our work
seeks to eliminate this possibility and support the deuterium exchange experiment in
eliminating the E1cB mechanism of the various possibilities discussed earlier.
To test for the E1cB type of mechanism, it was necessary to create mutant that lacked
the catalytic acid, responsible for donating a proton to the leaving phosphate group. The H106
residue was identified as the catalytic acid previously and was successfully created using site
directed mutagenesis. Another lab member, Vyacheslav Kuznetsov, carried out deuterium
isotope exchange experiments using this mutant.
Since the mutant lacked the catalytic acid, the reaction would remain incomplete. In the
case of an E1cB mechanism being employed by SpvC (Equation 2, Table 1) depending on the
rate-limiting step, different results would be observed. As stated earlier, it was our objective to
test for the formation of a carbanion intermediate at the active site. An incomplete reaction due
to lack of a catalytic acid would provide sufficient time for the reverse reaction, wherein the
deprotonated substrate would pick up a deuterium atom from the solvent (buffered D2O).
The substrate was incubated with the mutant enzyme in buffered D2O. The substrate
was then isolated and analyzed using mass spectrometry to determine the incorporation of
deuterium on he C-α. The presence of deuterated C-α would indicate that a carbanion
intermediate forms, and that the enzyme is capable of stabilizing such a species in the native
reaction. Such a carbanion intermediate might undergo elimination rapidly (in other words,
carbanion formation is rate-determining) or slowly, with elimination rate determining. If the
first possibility is the case, then deuterium exchange might be observed even with the wild type
enzyme. The H106N mutation hinders the elimination step, thus if the enzyme does form a
carbanion intermediate, its only path is in the reverse direction, reprotonation by an
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exchangeable proton (or deuteron) from the solvent. If, on the other hand, a concerted
elimination reaction takes place with no carbanion intermediate, then no deuterium exchange
will be observed even in the H106N mutant.
The lack of deuterium exchange at the C-α presents us with one of two possibilities –


That SpvC does not dephosphorylate the phosphothreonine residue using
carbanion intermediate, hence the lack of deuterium exchange at the C-α.



The mutation of the H106N residues created a structural anomaly that renders
the enzyme incapable of binding to the substrate peptide, thus resulting in lack
of deuterium exchange.

Using the same purification strategy as the wild type SpvC, we successfully purified the SpvC
H106N mutant. It was found that the mutant enzyme on incubation with the synthetic peptide
did not release inorganic phosphate, as determined by phosphomolybdate assay16. Since we had
created a mutant that altered an active site residue, it was necessary to verify the structural
integrity of the purified mutant.
As described in the previous chapter, X-ray crystallography was used to determine the
structure of our WT structure (4HAH) and mutant (4H43). The wild type structure obtained in
this project was compared with the previously published structure of ligand free SpvC WT
(2Z8M). It has been confirmed that the new structures retain their structural integrity despite
the use of new purification and crystallization protocols. Our experimentation has shown that
the SpvC WT, purified and crystallized by in this study, is active and is able to bind to the
substrate effectively. Structural studies of SpvC H106N mutant have shown that the WT and the
H106N mutant structure have no significant structural differences. The detailed comparison of
the mutant with the wild type structures described in the preceding section reveal no structural
changes in H106N mutant that would significantly affect binding of the substrate. While the

41
present structural investigation does not directly measure the ability of the H106N mutant to
bind the substrates used in either the kinetics or deuterium exchange experiments, the present
results document the lack of any structural consequences of the mutation.
The structural data obtained in this project therefore supports the conclusion that the
lack of deuterium on the phosphopeptide implies that the enzyme class does not utilize the
mechanism involving the formation of a carbanion (E1cB). While there exists the possibility of
several other mechanisms, through our presented work, we have successfully eliminated the
E1cB type reaction mechanism. These structural results also support the conclusion of an earlier
study that the lack of activity of the histidine mutant implicates it as a catalytic residue,8 and is
not due to structural perturbations.
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CHAPTER 6
CONCLUSION

Phosphothreonine lyases form a class of enzymes that are relatively new and are of
great significance in development of drugs against disease causing pathogens like Salmonella
and Shigella. Our objective has been to expand the understanding of this class of proteins by
understanding the mechanism used by the proteins to carry out dephosphorylation.
Through our work we have gained some knowledge about the mechanistic aspects of
the enzyme SpvC, which we believe will aid the scientific community in understanding
phosphothreonine lyases. We have:


Created a new plasmid carrying the protein with 10x His-tagged recombinant SpvC with
TEV cleavage site. This creates a recombinant SpvC with only one residue from the
cleavage site on the N-terminus as compared to previously published recombinant SpvC.
The presence of fewer amino acids from tags and cleavage sites results in lesser packing
irregularities during crystallization.



Developed a new and easily reproducible purification protocol that results in OspF and
SpvC of purity greater than 95%.



Crystallized and solved the previously unreported structure of the SpvC H106N mutant
In doing so, we have verified that the H106N (PDB ID 4H43) mutant retains all structural
aspects of the active wild type protein (PDB ID 4HAH) with only minor differences in the
position of the movable R220 loop.



Results

from

our

deuterium

isotope

exchange

experiment

indicate
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that

phosphothreonine lyase catalyzes the dephosphorylation without the formation of a
carbanion intermediate.
Our work allows us to narrow down the mechanistic possibilities that can be involved in
the elimination of the phosphate group by phosphothreonine lyases. This will aid future
research in developing mechanism-based inactivators of phosphothreonine lyases.
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